984 related articles for article (PubMed ID: 29477930)
21. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
[TBL] [Abstract][Full Text] [Related]
22. [Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Pi C; Zhang YC; Xu CR; Zhou Q
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):94-97. PubMed ID: 28219202
[TBL] [Abstract][Full Text] [Related]
23. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
Zhou C; Yao LD
J Thorac Oncol; 2016 Feb; 11(2):174-86. PubMed ID: 26845114
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
26. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
Chuang JC; Salahudeen AA; Wakelee HA
Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
[TBL] [Abstract][Full Text] [Related]
27. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Wang S; Song Y; Liu D
Cancer Lett; 2017 Jan; 385():51-54. PubMed ID: 27840244
[TBL] [Abstract][Full Text] [Related]
28. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
Castellanos EH; Horn L
Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
[TBL] [Abstract][Full Text] [Related]
29. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
Asami K
Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
33. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG; Shih JY
Mol Cancer; 2018 Feb; 17(1):38. PubMed ID: 29455650
[TBL] [Abstract][Full Text] [Related]
34. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].
Chen XX; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):401-404. PubMed ID: 28635227
[TBL] [Abstract][Full Text] [Related]
36. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
37. Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
Baglivo S; Ludovini V; Sidoni A; Metro G; Ricciuti B; Siggillino A; Rebonato A; Messina S; Crinò L; Chiari R
Mayo Clin Proc; 2017 Aug; 92(8):1304-1311. PubMed ID: 28778263
[TBL] [Abstract][Full Text] [Related]
38. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
39. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Tartarone A; Lerose R
Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
[TBL] [Abstract][Full Text] [Related]
40. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]